2341. Trends in Adenovirus Infections in Singapore Children and Outcomes of Cidofovir Treatment in the Severely Ill. (26th November 2018)

• Record Type: Journal Article
• Authors: Seah, Valerie Xue Fen; Chew, Yirong; Thoon, Koh Cheng; Tee, Nancy Wen Sim; Cui, Lin; Chong, Chia Yin; Yung, Chee Fu; Maiwald, Matthias; Tanugroho, Raymond Reinaldo; Tan, Natalie Woon Hui
• Is Part Of: Open forum infectious diseases. Volume 5(2018)Supplement 1
• Page Start: S695
• Page End: S696
• Publication Date: 2018-11-26
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofy210.1994
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: An increase in human adenovirus (HAdV) infections among hospitalized children in Singapore was observed since 2013. Cidofovir is often used to treat severe HAdV infections despite limited data. This study describes the epidemiology and outcomes of children with severe HAdV disease requiring high dependency (HD) or intensive care unit (ICU) admission in our hospital (KKH). Methods: This is a retrospective cohort study of HAdV-infected children admitted to HD and ICU in KKH from January 2013 to September 2017. Characteristics and outcomes of those who received IV cidofovir was also reviewed. Results: HAdV admissions and genotype profiles in KKH are described in Figures 1 and 2, respectively. There were 85 children with severe HAdV infection, of which 17 (20%) received cidofovir for mainly viremia (8, 47.1%) and pneumonia (7, 41.2%). Of these 17 patients, 7 (41.2%) died. More children treated with cidofovir had genotype 7 infection (8 of 17, 47.1%) vs. 13 of 68 (19.1%) who did not ( P = 0.027). Characteristics of patients who received cidofovir are described in Table 1. None experienced adverse reactions from cidofovir. All are n (%) unless stated otherwise. Conclusion: More children with HAdV genotype 7 infection required cidofovir treatment. HAdV pneumonia and ICU admission are potential risk factors for mortality despite cidofovir treatment. Disclosures: All authors: No reported disclosures.